Biocept, Inc. (BIOC) financial statements (2022 and earlier)

Company profile

Business Address 9955 MESA RIM ROAD
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 14,3689,3013,4232,1474,6098,821
Cash and cash equivalents 14,3689,3013,4232,1474,6098,821
Receivables 14,1453,5271,5741,19312934
Inventory, net of allowances, customer advances and progress billings 1,930768587499549349
Inventory 1,930768587499549349
Other undisclosed current assets 2,152296426417485436
Total current assets: 32,59413,8936,0114,2555,7729,641
Noncurrent Assets
Finance lease, right-of-use asset 2,3381,606
Operating lease, right-of-use asset 9,776729
Property, plant and equipment 2,3181,5042,7393,1241,806946
Other noncurrent assets 426     
Total noncurrent assets: 14,8583,8402,7393,1241,806946
TOTAL ASSETS: 47,45217,7338,7507,3797,57810,587
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 11,5313,9923,9683,0222,1211,599
Accounts payable 8,3652,0122,0401,270960633
Accrued liabilities 3,1661,9801,9281,7521,160967
Debt 9641,5676421,5782,1971,699
Other undisclosed current liabilities    617642
Total current liabilities: 12,4945,5594,6104,6614,3943,341
Noncurrent Liabilities
Long-term debt and lease obligation 11,2659739851,1501,9022,930
Long-term debt, excluding current maturities     1,1232,638
Finance lease, liability 1,460973
Capital lease obligations9851,150779291
Operating lease, liability 9,805 
Liabilities, other than long-term debt   113271397470
Deferred revenue and credits271397470
Deferred rent credit   113
Other undisclosed noncurrent liabilities (9,805)   227154
Total noncurrent liabilities: 11,2659731,0981,4222,5263,553
Total liabilities: 23,7596,5325,7086,0836,9206,894
Stockholders' equity
Stockholders' equity attributable to parent 23,69211,2013,0431,2966593,693
Common stock 150422
Additional paid in capital 287,218256,912223,500196,542174,293158,927
Accumulated deficit (263,527)(245,717)(220,458)(195,250)(173,636)(155,237)
Total stockholders' equity: 23,69211,2013,0431,2966593,693
TOTAL LIABILITIES AND EQUITY: 47,45217,7338,7507,3797,57810,587

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 27,4615,5293,2505,0693,223610
Revenue, net17,183  
Other income     154102
Cost of revenue (21,337)(10,978)(10,052)(9,345)(6,920)(4,596)
Gross profit: 6,125(5,449)(6,801)(4,276)(3,697)(3,986)
Operating expenses (21,593)(17,608)(17,457)(16,898)(14,328)(12,425)
Operating loss: (15,468)(23,057)(24,259)(21,175)(18,025)(16,411)
Nonoperating expense (2,339)(2,081)(311)(431)(372)(537)
Interest and debt expense (237)(250)(311)(483)(526)(640)
Loss from continuing operations before equity method investments, income taxes: (18,043)(25,388)(24,881)(22,089)(18,923)(17,588)
Other undisclosed income from continuing operations before income taxes 237250311483526640
Loss from continuing operations before income taxes: (17,807)(25,138)(24,570)(21,606)(18,397)(16,948)
Income tax expense   (2)(8)(2)(2)
Net loss attributable to parent: (17,807)(25,138)(24,572)(21,614)(18,399)(16,950)
Other undisclosed net loss available to common stockholders, basic (3)(122)(636)   
Net loss available to common stockholders, diluted: (17,810)(25,260)(25,208)(21,614)(18,399)(16,950)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (17,807)(25,138)(24,572)(21,614)(18,399)(16,950)
Comprehensive loss, net of tax, attributable to parent: (17,807)(25,138)(24,572)(21,614)(18,399)(16,950)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: